Lonza Expands Ibex TM Solutions to Offer Complete Product Lifecycle Management in One Location
(WorldNews Switzerland)

CHF 400 million investment in Lonza`s biopark in Visp (CH) to expand IbexTM Solutions with two innovative offerings The expansion includes drug substance development and drug substance and drug product manufacturing, which allows customers to manage the complete product lifecycle in one site Advanced technology, single-use bioreactors and improved platform processes shorten time to clinic and to market, while innovative business models will increase predictability Basel, Switzerland, 20 September 2018 - Lonza announces the addition of two new IbexTM Solutions offerings to Lonza`s...